pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
737
stories
Oct 14, 26
Zealand inks up to $1.3B deal for AI-designed obesity treatments
endpoints
Oct 14, 26
Deep-pocketed Verdiva axes GLP-1 switching trial over ‘market evolution’
fiercebiotech
Oct 14, 26
Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced
fiercebiotech
Oct 14, 26
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline
fiercebiotech
Oct 13, 26
Another Paragon spinout goes public through reverse merger
biopharma dive
Oct 13, 26
STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds
stat
Oct 13, 26
Verdiva cans mid-stage obesity trial of GLP-1 pill, citing 'market evolution'
endpoints
Oct 13, 26
Roche extends China deal streak with $1B pact for RNAi obesity drug
biopharma dive
Oct 13, 26
Roche expands obesity R&D footprint with Rona deal worth $1B+
biospace
Oct 13, 26
STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more
stat
Oct 13, 26
Roche's seventh China deal this year is a $1.2B obesity pact with Rona Therapeutics
endpoints
Oct 13, 26
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
fiercebiotech
Oct 13, 26
Recon: Roche inks $1.2B deal with China's Rona for obesity drug; Stryker invests $400M in CMR Surgical
raps
Oct 12, 26
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
Oct 9, 26
STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds
stat
Oct 9, 26
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
biopharma dive
Oct 9, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Oct 9, 26
STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
stat
Oct 9, 26
Viking commercial chief is out in a hurry; Gilead looks to BeOne exec for China expansion
endpoints
Oct 9, 26
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
Oct 8, 26
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
Oct 8, 26
NIH funding uncertainty thwarts U.S. researchers
stat
Oct 8, 26
STAT+: Roche goes beyond licensing in deal with Chinese biotech
stat
Oct 8, 26
Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle
endpoints
Oct 8, 26
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
Oct 8, 26
STAT+: Pharmalittle: We’re reading about PhRMA suing Trump, biotech frustration over tariffs, and more
stat
Oct 8, 26
Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar data
fiercebiotech
Oct 7, 26
WHO advises against obesity drugs for younger children
endpoints
Oct 7, 26
STAT+: Merck suffers a setback in Europe over its new Keytruda formulation
stat
Oct 7, 26
STAT+: Forbion raises $2.6 billion, its largest fundraise to date
stat
← prev
page 6 of 25
next →